Opinion|Videos|July 24, 2024
Key Takeaways in Renal Cell Carcinoma from Abstract 4512
Author(s)Martin H. Voss, MD, Moshe Ornstein, MD, MA
The panel examines the key findings from abstract 4512 and evaluates its potential impact on the current treatment paradigm for renal cell carcinoma.
Advertisement
Episodes in this series
Advertisement
Related to this article
Ethan B. Ludmir, MD, details which cholangiocarcinoma subsets, by tumor location, may benefit most from neoadjuvant radiation before surgery.
Data from the phase BRUIN CLL-313 and BRUIN CLL-314 trials support the approval of pirtobrutinib for patients with CLL or SLL in China.
Clinicians must think a lot about how to make testing and novel treatment advances available for patients globally, according to Chul Kim, MD, MPH.
Daniel C. McFarland, DO, and Yesne Alici, MD, discussed medical aid in dying in cancer care, New York’s safeguards, and the role of psycho-oncology.
Ethan B. Ludmir, MD, explains the rationale for moving radiation into the neoadjuvant setting for borderline resectable cholangiocarcinoma.
An analysis of the BENEFIT trial supports isatuximab plus bortezomib, lenalidomide, and dexamethasone as a new standard of care in transplant-ineligible NDMM.
C. Ola Landgren, MD, PhD, discusses how MRD-driven strategies may eliminate the transplant-eligible vs transplant-ineligible framework in multiple myeloma.
Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
2
Isatuximab-Based Therapy Shows “Impressive” PFS Projections in NDMM
3
Durvalumab Plus Enfortumab Vedotin Earns FDA Priority Review in MIBC
4
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
5